BioCentury | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...function. By year-end, IM Therapeutics expects to begin preclinical development of small molecule inhibitors of HLA-DQ2...
...N.Y. Tolerion Inc., Portola Valley, Calif. Virobay Inc., Menlo Park, Calif. Targets HLA-Human leukocyte antigen HLA-DQ2-Major histocompatibility complex class II DQ2...
...II DQ8 MHCI-Major histocompatibility complex class I Jaime de León, Staff Writer IMT-002 VBY-129 ImmunoMolecular Therapeutics LLC Virobay Inc. Cathepsin S (CTSS) Major histocompatibility complex class II DQ2 (HLA-DQ2) Major...
BioCentury | Nov 10, 2017
Company News

IM Therapeutics launches with T1D candidate

...to investigate a similar approach to treat additional autoimmune diseases including celiac disease, for which HLA-DQ2...
...LLC, Broomfield, Colo. University of Colorado School of Medicine, Aurora, Colo. Business: Endocrine/Metabolic Mary Romeo JDRF University of Colorado HLA-DQ2 Human...
BioCentury | Nov 9, 2017
Company News

IM Therapeutics emerges from stealth with small molecule for T1D

...celiac disease, for which HLA-DQ2 has been identified as an immune recognition gene. Mary Romeo University of Colorado HLA-DQ2 Major...
BioCentury | Feb 19, 2015
Product R&D

Banking on stem cells

...super donor type is homozygous at the five HLA loci: HLA-A1, HLA-B8, HLA-C7, HLA-DR17, and HLA-DQ2...
...histocompatibility complex class I C7 HLA-DR17 - Major histocompatibility complex class II DR17 HLA-DQ2 - Major histocompatibility complex class II DQ2...
BioCentury | Mar 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Insulin Mouse studies suggest antibodies that prevent the recognition of specific autoimmunogenic insulin complexes could help treat type 1 diabetes. mAbs were produced...
BioCentury | Jan 23, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Orexin (hypocretin; HCRT)-based immunoassays to diagnose narcolepsy Immunoassays to determine T cell reactivity to two HCRT epitopes could be used to diagnose narcolepsy. Narcolepsy...
BioCentury | Mar 26, 2012
Emerging Company Profile

ImmusanT: Having their cake

...for a T cell response in the 80-90% of celiac disease patients who carry the major histocompatibility complex class II DQ2 (HLA-DQ2)...
...plans to start two trials to assess the safety and tolerability of the vaccine in HLA-DQ2-positive...
...T cell response using ImmusanT's diagnostic, which is in early validation testing. "Patients who are HLA-DQ2-positive...
BioCentury | Dec 19, 2011
Finance

Bread for celiac vaccine

...it is suitable for 80-90% of celiac disease patients who carry the immune recognition gene HLA-DQ2...
Items per page:
1 - 10 of 22